FDA Approves Jemperli Immunotherapy for Rectal Cancer

The FDA has granted accelerated approval for Jemperli (dostarlimab-gxly), an immunotherapy, to treat certain patients with locally advanced rectal cancer. This approval offers a new treatment option for individuals with microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) tumors, potentially allowing them to avoid standard treatments like chemotherapy, radiation, and surgery, which often carry significant long-term side effects. This represents a notable advancement in oncology.